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Abstract  
Background The rate of acquired HIV-1 drug resistance (ADR) has fallen dramatically since introduction 
of combined antiretroviral therapy (cART) in Switzerland. However, clinical experience indicates that 
there are still patients at risk of newly acquiring drug resistance despite having access to cART. Here, we 
characterized risk factors for ADR, in order to improve patient care, prevent emergence of drug resistance, 
and treatment failure.  
 
Methods We performed a case-control study to identify risk factors for ADR in all patients starting their 
first cART in the Swiss HIV Cohort Study (SHCS) since 1996. The SHCS is highly representative and 
includes over 75% of patients receiving ART in Switzerland.  To this end, we implemented a systematic 
medical chart review to obtain more detailed information on additional parameters, which are not 
routinely collected in the SHCS. The collected data was analyzed univariable and multivariable conditional 
logistic regressions. 
 
Results We included in our study 115 cases and 115 matched controls. Unemployment (mOR 2.9 (95% CI: 
1.3-6.4), p=0.008), African origin (mOR3.0 (95%CI: 1.0-9.2), p=0.047), co-medication with anti-infectives 
(mOR 3.6 (95%CI: 1.0-12.6), p=0.045) and symptoms of mental illness (mOR 2.6 (95% CI: 1.2-5.5), 
p=0.012) were associated with ADR in the multivariable model.  
 
Conclusions Although, ADR has become very rare with cART due to new potent therapies, patients in 
socially challenging life situations or presenting with mental health issues are at higher risk for drug 
resistance. Prompt identification and adequate support of these patients before ADR will prevent 
treatment failure and HIV-1 transmission.  
 
Keywords (5) HIV-1 drug resistance, risk factors, antiretroviral therapy, socioeconomic factors 
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Introduction  
 
Emergence of HIV- 1 drug resistance has become less frequent with the introduction of combination 
antiretroviral treatment (cART) [1-7] due to its high effectiveness at suppressing human 
immunodeficiency virus (HIV) replication in infected individuals [8-10].  
Consequently, in resource-rich settings with continuous access to cART and HIV-related care, HIV 
infection has become a controllable chronic illness with life expectancy approaching that of the general 
population [11-13]. However, clinical experience indicates that there are still patient groups at risk of 
newly acquiring drug resistance despite having access to cART [14]. Several studies indicate that low 
socioeconomic status (SES ) not only increases vulnerability to HIV infection and is associated with having 
poorer virological and immunological outcomes, but also impedes engagement and retention of HIV-
infected persons in clinical care [15-20]. Some European studies have also shown that lower 
socioeconomic status is associated with non- adherence to ART [20]. Non-adherence and subsequent drug 
resistance therefore still poses a major obstacle to successful treatment and elimination of HIV- 1 
transmission in resource-rich settings [7, 21, 22].  
In contrast, in resource limited settings rising rates of acquired drug resistance may not only reflect poor 
adherence but also shortage of optimal regimens, and a lack of viral load monitoring. Cost and laboratory 
availability limit monitoring severely and pose the major hurdles for successful treatment [23].  For public 
health and prevention strategies, and to assess requirements for new drugs, it is important to monitor the 
spread of drug resistance in the HIV-infected population [7]. Moreover, in resource- rich settings, it is 
crucial to analyze risk factors leading to resistance in the presence of already highly active antiretroviral 
therapy. Once risk factors are identified, patients at risk can be followed up closely and support can be 
intensified. 
In the current study, we retrospectively characterize risk factors and examine sociodemographic 
correlates for the development of drug resistance in a nation-wide sample of HIV-positive patients 
receiving cART after 1996. 
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Methods  
 
Study population and design 
We performed a case-control study to identify risk factors for acquired HIV-1 drug resistance (ADR) in 
patients starting their first cART regimen in the Swiss HIV Cohort Study (SHCS). The SHCS is an ongoing, 
nationwide, multicenter, clinic-based, observational study with continuous enrollment and semiannual 
study visits. At least 75% of all HIV-1 diagnosed adults receiving cART in Switzerland are enrolled in the 
SHCS. The SHCS has been approved by the ethical committees of all participating institutions, and written 
informed consent has been obtained from all participants [24]. The SHCS has a linked drug resistance 
database, which includes sequences from genotypic resistance tests (GRTs) performed by the four 
authorized laboratories in Switzerland. Over 12’000 sequences were generated retrospectively from the 
biobank to also cover treatment failing episodes and transmitted drug resistance, when drug resistance 
testing was not performed routinely [25]. Sequences are stored in a central database (SmartGene; 
Integrated Database Network System version 3.8.1). All laboratories performed population-based 
sequencing [2, 25]. Acquired drug resistance has been defined as the occurrence of at least one major 
mutation listed by the International Antiviral Society–USA [22]. 
We restricted the analysis to patients who received potent cART defined as treatment with at least three 
drugs from two different drug classes [Nucleoside analog reverse-transcriptase inhibitors 
(NRTI), Non-nucleoside reverse-transcriptase inhibitors (NNRTI), boosted Protease inhibitor (PI), 
integrase inhibitor, or entry inhibitor]. Patients who had in their medical history an exposure to 
mono/dual/triple NRTI therapies or regimens including unboosted PIs were excluded from the analysis. 
We identified 115 cases that acquired a drug resistance mutation, proven by a GRT, after cART initiation. 
Subsequently, we randomly matched 115 controls (1:1) based on the following criteria: Plasma HIV-1 
RNA at treatment initiation [<1000 copies/mL, 1000-9999 copies/mL, ≥10000 copies/mL], CD4 cell count 
at baseline (0-99 cells/µL, 100-199 cells/µL, > 200 cells/µL), year of cART initiation [<1998, 1999-2006, 
>2006], presence of a baseline drug resistance mutation, and the SHCS study center (Basel, Berne, Geneva, 
Lausanne, Lugano, St. Gallen, Zürich) [Supplementary Table 1]. The latter was implemented to exclude 
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documentation and treatment bias between the SHCS centers. The follow-up time of the controls (cART 
initiation until last follow-up) had to be at least as long as for the cases (cART initiation until detection of 
ADR).  
 
Potential risk factors for acquired drug resistance 
In addition to the routinely collected data in the SHCS [24] we hypothesized that additional factors which 
are not routinely documented in the six monthly questionnaire could be associated with acquired drug 
resistance mutations. Therefore, we additionally defined potential relevant factors relevant for acquiring 
drug resistance that were not documented in the SHCS protocol and subsequently performed a medical 
chart review on all 230 patients and collected detailed information beyond the documented SHCS 
questionnaire [Supplementary Table 2]. We not only looked at the medical chart documentation at the 
time point of GRT and the previous visits (all visits in the 6 months prior to GRT) but also screened all 
available admission letters and hospitalization documentation during the 6 months prior to GRT. We did 
not include any time points after GRT in our analysis. As depression is frequent among HIV infected 
persons [26, 27] and the presence of mental health disorders has been found to correlate with reduced 
adherence [28], we analyzed medical chart documentation for symptoms of mental illness,  diagnosis of 
mental health disorders and for documented psychiatric treatment (psychiatric hospitalization, outpatient 
mental health treatment, treatment by a psychiatrist or psychiatric medication). 
We systematically looked at the three monthly visit documentation up to 6 months prior to GRT. 
To evaluate whether co-infections or complicated medication regimens (due to additional treatment of 
infections) may have led to adherence problems we screened for co-medication with anti-infectives in the 
6 months prior to and at the time point of GRT.  We screened whether the patients had an additional 
treatment with antibiotic, antimycobacterial, antifungal, antiviral (other than ART) or antiparasitic 
medication. Additionally we screened specifically what medication was prescribed and whether drug-
drug interactions were expected. We also screened for documented ART drug level measurements (see 
Supplementary Table 2). 
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Additionally, as we hypothesized that difficulties in communication and reduced information might 
largely affect adherence, we specifically looked for language barrier. Language barrier was defined when 
in the medical chart it was clearly stated that the patient and doctor could not communicate as they did 
not speak the same language. In the SHCS this applies to patients who do not speak French, Italian, 
German or English. 
Self-reported adherence in the SHCS questionnaire has been previously validated to predict viral failure, 
HIV drug resistance and mortality [29-31]. 
Statistical analysis 
We performed univariable and multivariable conditional logistic regression to identify risk factors for 
ADR. We included factors from the univariable model with a p-value <0.1 in the multivariable models or 
factors, which were previously known to be associated with drug resistance. We systematically looked for 
collinear factors. If identified, we have only included one of these factors in the multivariable model. We 
performed sensitivity analyses including only patients with a perfect match based on the above-
mentioned criteria.  We did not include self-reported adherence in the final multivariable analysis, only in 
a sensitivity analysis, as adherence is most likely on the causal path towards acquired drug resistance. We 
performed statistical analyses with Stata (version 15.1/SE; Stata Corporation, College Station, Texas, USA). 
 
Results  
 
Study Population 
The selection of the 115 patients with acquired HIV-1 drug resistance (ADR) after cART initiation is 
depicted in the flow chart [Supplementary Figure 1]. All patients started directly with ≥3 drugs from at 
least two different drug classes. The year of cART initiation was subdivided in 3 categories: (1) before 
1999 for 6 (1.7%), (2) between 1999-2006 for 78 (67.8%) and (3) after 2006 for 31 patients (27%).  
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Overall 91 (79.1%) cases and 93 (80.9%) controls had a baseline viral load > 10’000 copies/ml. The 
median [IQR] baseline viral load was 5.2 [4.9 - 5.7] and 5.1 [4.7-5.6] log10 RNA copies/mL in cases and 
controls, respectively. High viral loads above 100’000 copies/mL were found in 65% of controls and 57% 
of cases. Pre-treatment drug resistance mutations were found in a minority of patients (n=18, 7.8%). In 
the study population 22 (19%) cases vs. 38 (33%) controls were MSM, 38 (33%) cases vs. 45 (39%) 
controls were heterosexual men, 43 (37%) cases vs. 27 (23%) controls were heterosexual women.  In the 
transmission group IDU 12 (10.4%) cases vs. 5 (4.3%) controls were identified. 
 
Sociodemographic factors largely determine the development of ADR 
We identified several risk factors, which strongly correlated with ADR in the univariable as well as in the 
multivariable model (Figure 1, Supplementary Table 3). First, we focused on origin of the patients and 
analyzed whether geographical and sociocultural background influenced adherence and ADR. We found a 
strong correlation with increased risk for developing ADR and African origin (multivariable odds ratio 
(mOR): 3.4, 95% CI 1.0-9.2, p 0.047). We further analyzed characteristics of this group (Figure 2 A). We 
found in the univariable model that being a migrant seeking for asylum was highly associated with ADR 
(uOR: 2.6, 95% CI: 1.1-6.0, p<0.023), as well as having a language barrier (uOR: 2.6, 95% CI: 1.4-4.7, 
p=0.002) or being female (uOR: 2.2, 95% CI: 1.2-3.8, p=0.007). Because of collinearity with the origin, we 
did not include these factors in the multivariable model.  
We also analyzed socioeconomic factors and found that unemployment bears a relevant risk (mOR 2.9 
95% CI: 1.3-6.4, p 0.008) (Figure 1, Supplementary Table 3). In a more detailed analysis of this 
subgroup (Figure 2 B), limited education (uOR: 3.3, 95% CI: 1.4-7.7, p=0.006), being an IDU (uOR: 3.9, 
95% CI: 1.2-12.9, p<0.021) and excessive consumption of alcohol were associated with ADR (uOR: 3.0, 
1.3-7.2, p<0.013). Because of the collinearity of these factors with unemployment, we did not include them 
in the multivariable model.  
On the contrary, having a stable income and being able to work >50% of the time was a strongly 
protective factor (uOR: 0.27, 95% CI: 0.14-0.52, p<0.001).  
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Overall, older age tended to have a protective effect upon ADR development (mOR per 10 years increase: 
0.73, 95% CI 0.5-1.0, p=0.073) (Figure 1, Supplementary Table 3). 
Importantly, when we analyzed only patients with a perfect match (N=144), we had an almost identical 
result, which confirms the robustness of the analysis (data not shown). 
 
Mental health issues severely impacts ADR  
We found that mental health issues correlated with ADR (Figure 1, Supplementary Table 3). A clear 
association of ADR to the documented diagnosis of depression (uOR 2.0, 95% CI 1.1, 3.8, p=0.029) (Table 
1) was ascertained. We analyzed whether side effects had an influence upon adherence and subsequently 
on ADR. We therefore additionally assessed side effects which can associate with mental health disorders 
and which are not included in the SHCS questionnaire. Nightmares (uOR 4.0, 95% CI 1.41, 7.66, p=0.007), 
mood swings (uOR 4.1, 95% CI 1.8, 9.4, p=0.001) and tiredness (uOR 4.7, 95% CI 1.6, 13.7, p=0.005) were 
associated with ADR (Table 1).  When analyzing only the subgroup of patient with diagnosed mental 
health disorders and which are in psychiatric treatment in the multivariable model, the key findings were 
corroborated (Supplementary Table 5). 
 
Co-medication with anti-infectives increases ADR 
We also studied whether a higher pill burden with co-medication led to an increased risk of ADR. We 
found that co-medication with anti-infectives (e.g. antibiotic, antimycobacterial, antifungal, antiviral 
(other than ART), antiparasitic medication) correlated with ADR (mOR 3.6 (95%CI: 1.0-12.6), p=0.045). 
We were not able to assess whether specific anti- infective therapy were leading to ADR as the sample size 
of the different subgroups was too small. We also analyzed whether there were possible drug-drug 
interactions or drug level measurements that explained why ADR developed in patients with anti-
infectives. However, no obvious drug-drug interactions were noticed and drug levels were rarely 
measured (only in 47 patients).  
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Adherence is associated with ADR 
As expected, low self- reported adherence is closely associated with the occurrence of drug resistance. 
Compared to controls, more cases missed the dose at least once a month (18.3% vs 15.7%) or at least once 
a week (36.5%vs. 2.6%). We did a sensitivity analysis including adherence in the multivariable model. The 
risk was 3.7 (95% CI: 1.2-11.6) and 9.4 (95% CI: 2.4-36.5) times increased among patients who missed the 
dose at least once a month or at least once a week, compared to patients who never missed a dose 
(Supplementary Table 4). However, we cannot confirm that it is associated with barriers to care as 
shown in other studies [14, 19, 32]. On the contrary, in our cohort we detected higher number of visits (> 
4 in 12 months) being correlated to ADR (OR 2.67, 95% CI 1.37, 5.18, p 0.004). This shows that in the 
SHCS patients at risk are more closely followed up before detection of ADR. However, the increased visit 
frequency seem not to be sufficient to avoid ADR. Whether low SES favored also an avoidance coping was 
not explored in this study. 
 
Unexplained cases of ADR 
Remarkably, patients with ADR and without any risk factor identified in the multivariable model (African 
origin, unemployment, co-medication with anti-infectives, mental health issues, age<45 years) were rarely 
identified (n=5 (4%). Patients with ADR had a median (IQR) of 3 (2-4) of the mentioned risk factors in the 
multivariable model (Figure 1). 
 
Discussion 
Although ADR has become very rare in Switzerland since the introduction of cART [6], full access to 
antiretroviral treatment, viral load monitoring as well as resistance testing, there are still individuals that 
experience treatment failure due to ADR. In this study, we clearly identified risk factors for emergence of 
drug resistance in this generally highly successfully treated patient population. 
One of the key results our study reveals is that the patient’s origin and sociocultural background largely 
affect treatment outcome. Being of black ethnicity, originating from Africa and arriving to Switzerland as 
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migrant seeking for asylum affects treatment success and leads to more ADR.  We also show that this is 
further aggravated when difficulties in communication with the health care team due to language barrier 
are met.  
When analyzing the influence of gender in the univariable model, being a woman is clearly more often 
associated with ADR. A possible explanation for this result may be the myriad of psychosocial stressors 
observed in women living with HIV, such as caregiving and household responsibilities, the already 
described financial related stressors and relationship problems [33-36]. In summary, additional to the 
psychosocial stressors of – mostly female- migrants, impaired communication and therefore obstacles due 
to misunderstanding largely affect treatment success. 
 
We also show that unemployment and limited education is associated with higher likelihood of developing 
drug resistance. Our findings support previous findings that low SES is associated with lower drug 
adherence [15-17]. However, we cannot confirm that it is associated with barriers to care as shown in 
other studies [14, 32]. On the contrary, the increased visit numbers before ADR show, that a problem in 
adherence and incumbent risk were noticed and a strong effort was put to improve patient care.  
Nevertheless, it shows that the mechanisms in place still were not strong enough to prevent ADR. These 
findings also highlight that different subgroups can experience similar stressors, which negatively impact 
adherence and subsequently lead to ADR. 
 
Psychological symptoms have been recognized to interfere with activities of daily life, physical 
functioning, interpersonal relationships and adherence [36, 37]. Our study shows a significant correlation 
between mental health issues and ADR. Also, the presence of side-effects associated with mental health 
issues or even disguising psychiatric problems (e.g. tiredness , mood swings, nightmares) also correlated 
with ADR. The described symptoms could therefore reflect an underlying and undiagnosed mental 
disorder- rather than ART associated side effects. Remarkably, no association was found to psychiatric 
treatment or co-medication with antidepressant. With the clear association of mental health issues and 
ADR, future improvement of patient care needs to focus not only on diagnosis mental health disorders but 
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also adequate treatment. Overall, our results corroborate previous findings showing a clear association 
between depression and non-adherence to ART [28, 38]. 
 
We found an association with co-medication with anti-infectives.  Polypharmacy impacts how drugs are 
tolerated, increases possible drug interaction and most importantly also leads to reduced adherence [39, 
40]. The association of anti-infectives with ADR might hint to more complicated drug regimens, more side 
effects and indirectly also towards more drug-drug interactions explaining this finding. In these patients 
with more complicated course of HIV infections, a more regular and close guidance during the time of 
multiple therapies is advised. [41]. 
 
The study has been systematically conducted in a prospectively followed, well characterized, 
representative patient population in a real world setting with full access, monitoring and resistance 
testing for all (at least 75% of all ART treated adults in Switzerland are enrolled in the SHCS[6]), which 
allowed a careful matched case control study and a detailed chart review. However, the study has 
limitations. The retrospective analysis of patient charts and the varying quality of documentation and 
sometimes missing information may have influenced the results. Moreover, the diagnosis of mental health 
issues was based on documentation by the treating infectious disease specialist and could have been 
incompletely documented. Importantly, the documentation and diagnosis of mental health issues will 
improve, as the SHCS cohort has implemented an exact questionnaire addressing these topics since 2014. 
 
In conclusion, we show that ADR is still of concern in the era of cART in vulnerable patient groups that 
face a multitude of challenges. The factors we identified here, i.e. lower education status, psychiatric 
comorbidities, being a migrant seeking for asylum, will help practitioners identify these patients early on. 
However, multidisciplinary efforts are likely needed to help patients to overcome these significant 
barriers to adherence, and might include social services, counseling, or a referral to a psychiatrist. This 
study suggests that with improved patient care and previous knowledge of the identified risk factors a 
further reduction of ADR can be achieved.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
14 
 
Author's contributions 
Conceived and designed the study: IA, AUS,, HFG, Performed the analysis: IA and AUS, Collected and 
contributed data: IA, AUS, JB, SY, TK, MP, MB, JF, AC, PS, MC, EB, HFG, Wrote the paper: IA, AS, HFG. All 
authors read and approved the final manuscript. 
Acknowledgements 
We thank the patients who participate in the Swiss HIV Cohort Study; the physicians and study nurses, for 
excellent patient care; the resistance laboratories, for high-quality genotyping drug resistance testing; 
SmartGene (Zug, Switzerland), for technical support; Alexandra Scherrer, Susanne Wild, Anna Traytel 
from the SHCS data center for data management, Danièle Perraudin and Mirjam Minichiello for 
administration. The members of the Swiss HIV Cohort Study include the following: 
Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, 
Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory 
Committee), Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse 
B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, 
Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Paioni P, 
Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Rudin C (Chairman of the Mother & 
Child Substudy), Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, 
Vernazza P, Wandeler G, Weber R, Yerly S. 
Funding 
This work was supported by the Swiss National Science Foundation (Grant # 179 571  to  HFG) and was  
financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science 
Foundation (grant #148522), by the SHCS research foundation by the Yvonne Jacob Foundation (to HFG), 
by the clinical research priority program of the University of Zurich “Viral infectious diseases, ZPHI” (to 
HFG). HFG has received an unrestricted research Grant from Gilead to the SHCS Research Foundation. 
Conflicts of interests 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
15 
 
HFG has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety 
monitoring board membership from Merck; consulting/advisory board membership fees from Gilead 
Sciences, Sandoz and Mepha, and grants from Systems.X, and NIH. MB has received research or 
educational grants by Abbvie AG, Gilead Sciences Switzerland Sàrl, Janssen-Cilag AG, MSD Merck Sharp & 
Dohme AG and ViiV Healthcare GmbH.  HF reports support to his institution for advisory boards and/or 
travel grants and/or educational grants from Janssen-Cilag, MSD, Gilead Sciences, Abbvie, and Bristol-
Myers Squibb, Viiv, Sandoz, and an unrestricted research grant from Gilead Sciences. AC has received 
unrestricted educational and research grants from MSD, Gilead and ViiVAll remuneration went to his 
home institution and not to AC personally, and all remuneration was provided outside the submitted 
work. MC has received research and travel grants for his institution from ViiV and Gilead, as well as 
payments from Abbvie and MSD. EB has received fees for his institution for participation to advisory 
board from MSD, Gilead Sciences, ViiV Healthcare, Sandoz, Pfizer, Abbvie and Janssen.  
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
16 
 
References 
 
1. Gulick, R.M., et al., Treatment with indinavir, zidovudine, and lamivudine in adults with 
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 
1997. 337(11): p. 734-9. 
2. von Wyl, V., et al., Emergence of HIV-1 drug resistance in previously untreated patients 
initiating combination antiretroviral treatment: a comparison of different regimen types. 
Arch Intern Med, 2007. 167(16): p. 1782-90. 
3. Dunn, D., et al., Population trends in the prevalence and patterns of protease resistance 
related to exposure to unboosted and boosted protease inhibitors. Antivir Ther, 2008. 
13(6): p. 771-7. 
4. Bontell, I., et al., Trends in antiretroviral therapy and prevalence of HIV drug resistance 
mutations in Sweden 1997-2011. PLoS One, 2013. 8(3): p. e59337. 
5. Buchacz, K., et al., Trends in Decline of Antiretroviral Resistance among ARV-Experienced 
Patients in the HIV Outpatient Study: 1999-2008. AIDS Res Treat, 2012. 2012: p. 230290. 
6. Scherrer, A.U., et al., Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in 
Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis, 2016. 62(10): p. 1310-
1317. 
7. Gunthard, H.F., et al., Human Immunodeficiency Virus Drug Resistance: 2018 
Recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis, 2018. 
8. Cameron, D.W., et al., Randomised placebo-controlled trial of ritonavir in advanced HIV-1 
disease. The Advanced HIV Disease Ritonavir Study Group. Lancet, 1998. 351(9102): p. 
543-9. 
9. Hammer, S.M., et al., A controlled trial of two nucleoside analogues plus indinavir in 
persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic 
millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med, 1997. 
337(11): p. 725-33. 
10. Gunthard, H.F., et al., Antiretroviral treatment of adult HIV infection: 2014 
recommendations of the International Antiviral Society-USA Panel. JAMA, 2014. 312(4): p. 
410-25. 
11. Antiretroviral Therapy Cohort, C., Life expectancy of individuals on combination 
antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort 
studies. Lancet, 2008. 372(9635): p. 293-9. 
12. Gueler, A., et al., Life expectancy in HIV-positive persons in Switzerland: matched 
comparison with general population. AIDS, 2017. 31(3): p. 427-436. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
17 
 
13. Katz, I.T. and B. Maughan-Brown, Improved life expectancy of people living with HIV: who 
is left behind? Lancet HIV, 2017. 4(8): p. e324-e326. 
14. Rocheleau, G., et al., Sociodemographic correlates of HIV drug resistance and access to 
drug resistance testing in British Columbia, Canada. PLoS One, 2017. 12(9): p. e0184848. 
15. Kinsler, J.J., et al., The effect of perceived stigma from a health care provider on access to 
care among a low-income HIV-positive population. AIDS Patient Care STDS, 2007. 21(8): 
p. 584-92. 
16. Cunningham, C.O., et al., Utilization of health care services in hard-to-reach marginalized 
HIV-infected individuals. AIDS Patient Care STDS, 2007. 21(3): p. 177-86. 
17. Leaver, C.A., et al., The effects of housing status on health-related outcomes in people living 
with HIV: a systematic review of the literature. AIDS Behav, 2007. 11(6 Suppl): p. 85-100. 
18. Chambers, L.A., et al., Stigma, HIV and health: a qualitative synthesis. BMC Public Health, 
2015. 15: p. 848. 
19. Giordano, T.P., et al., Retention in care: a challenge to survival with HIV infection. Clin 
Infect Dis, 2007. 44(11): p. 1493-9. 
20. Burch, L.S., et al., Socioeconomic status and response to antiretroviral therapy in high-
income countries: a literature review. AIDS, 2016. 30(8): p. 1147-62. 
21. Larder, B.A., G. Darby, and D.D. Richman, HIV with reduced sensitivity to zidovudine (AZT) 
isolated during prolonged therapy. Science, 1989. 243(4899): p. 1731-4. 
22. Wensing, A.M., et al., 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir 
Med, 2017. 24(4): p. 132-133. 
23. Murphy, R.A., et al., Outcomes after virologic failure of first-line ART in South Africa. AIDS, 
2010. 24(7): p. 1007-12. 
24. Swiss, H.I.V.C.S., et al., Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol, 2010. 
39(5): p. 1179-89. 
25. Yang, W.L., et al., Assessing the Paradox Between Transmitted and Acquired HIV Type 1 
Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. J Infect Dis, 
2015. 212(1): p. 28-38. 
26. Anagnostopoulos, A., et al., Frequency of and Risk Factors for Depression among 
Participants in the Swiss HIV Cohort Study (SHCS). PLoS One, 2015. 10(10): p. e0140943. 
27. Bing, E.G., et al., Psychiatric disorders and drug use among human immunodeficiency virus-
infected adults in the United States. Arch Gen Psychiatry, 2001. 58(8): p. 721-8. 
28. Gonzalez, J.S., et al., Depression and HIV/AIDS treatment nonadherence: a review and 
meta-analysis. J Acquir Immune Defic Syndr, 2011. 58(2): p. 181-7. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
18 
 
29. Glass, T.R., et al., Determinants of sustained viral suppression in HIV-infected patients with 
self-reported poor adherence to antiretroviral therapy. PLoS One, 2012. 7(1): p. e29186. 
30. von Wyl, V., et al., Adherence as a predictor of the development of class-specific resistance 
mutations: the Swiss HIV Cohort Study. PLoS One, 2013. 8(10): p. e77691. 
31. Glass, T.R., et al., Self-reported nonadherence to antiretroviral therapy as a predictor of 
viral failure and mortality. AIDS, 2015. 29(16): p. 2195-200. 
32. Giordano, T.P., Retention in HIV care: what the clinician needs to know. Top Antivir Med, 
2011. 19(1): p. 12-6. 
33. Durvasula, R., HIV/AIDS in older women: unique challenges, unmet needs. Behav Med, 
2014. 40(3): p. 85-98. 
34. Catz, S.L., C. Gore-Felton, and J.B. McClure, Psychological distress among minority and low-
income women living with HIV. Behav Med, 2002. 28(2): p. 53-60. 
35. Cederfjall, C., et al., Gender differences in perceived health-related quality of life among 
patients with HIV infection. AIDS Patient Care STDS, 2001. 15(1): p. 31-9. 
36. Ickovics, J.R., et al., Mortality, CD4 cell count decline, and depressive symptoms among HIV-
seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. 
JAMA, 2001. 285(11): p. 1466-74. 
37. Arseniou, S., A. Arvaniti, and M. Samakouri, HIV infection and depression. Psychiatry Clin 
Neurosci, 2014. 68(2): p. 96-109. 
38. Starace, F., et al., Depression is a risk factor for suboptimal adherence to highly active 
antiretroviral therapy. J Acquir Immune Defic Syndr, 2002. 31 Suppl 3: p. S136-9. 
39. Kamal, S., et al., HIV-infected patients' beliefs about their chronic co-treatments in 
comparison with their combined antiretroviral therapy. HIV Med, 2018. 19(1): p. 49-58. 
40. Marzolini, C., et al., Ageing with HIV: medication use and risk for potential drug-drug 
interactions. J Antimicrob Chemother, 2011. 66(9): p. 2107-11. 
41. Ballester-Arnal, R., et al., A Spanish Study on Psychological Predictors of Quality of Life in 
People with HIV. AIDS Behav, 2016. 20(2): p. 281-91. 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
19 
 
Table 1: Univariable conditional logistic regression looking at the association of mental health 
issues and acquired drug resistance 
 Control 
(n=115) 
Cases 
(n=115) 
uOR (95% CI) p-value 
Depression      
No 90 (78%) 74 (64%) Ref   
Yes 23 (20%) 37 (32%) 2.0 (1.1-3.8) 0.029 
Unknown 2 (2%) 4 (3%) 2.6 (0.5-14.6) 0.286 
Psychiatric 
treatment 
     
No 92 (80%) 81 (70%) Ref   
Yes 21 (18%) 31 (27%) 1.6 (0.9-3.0) 0.117 
Unknown 2 (2%) 3 (3%) 1.8 (0.3-11.3) 0.513 
Mood swings      
No 101 
(88%) 
66 (57%) Ref   
Yes 9 (8%) 27 (23%) 4.1 (1.8-9.4) 0.001 
Unknown 5 (4%) 22 (19%) 6.7 (2.2-20.3) 0.001 
Nightmares      
No 102 
(89%) 
72 (63%) Ref   
Yes 8 (7%) 21 (18%) 4.0 (1.4-11.0) 0.007 
Unknown 5 (4%) 22 (19%) 5.7 (1.9-16.8) 0.002 
Sleeping disorder      
No 95 (83%) 69 (60%) Ref   
Yes 15 (13%) 24 (21%) 2.2 (1.0-4.7) 0.056 
Unknown 5 (4%) 22 (19%) 5.7 (1.9-16.7) 0.002 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz178/5370584 by E-Library Insel user on 12 M
arch 2019
 
20 
 
Tiredness      
No 102 
(89%) 
73 (63%) Ref   
Yes 5 (4%) 16 (14%) 4.7 (1.6-13.7) 0.005 
Unknown 8 (7%) 26 (23%) 4.6 (1.9-11.3) 0.001 
Alcohol abuse      
No 100 
(87%) 
82 (71%) Ref   
Yes 7 (6%) 20 (17%) 3.0 (1.3-7.2) 0.013 
Unknown 8 (7%) 13 (11%) 1.9 (0.7-5.0) 0.172 
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Figure legends 
Figure 1: Risk factors for acquired drug resistance under ART. Univariable and multivariable 
conditional logistic regression 
Figure 2: Detailed analyses of sociocultural and socioeconomic factors based on origin (A) and 
job situation (B). p-values are based on Fisher's exact test 
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Figure 1 
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Figure 2 
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